Cargando…

Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial

AIM: To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase‐4 (DPP‐4) inhibitor, as an add‐on therapy in patients with type 2 diabetes (T2D) that is inadequately controlled with metformin. MATERIALS AND METHODS: In this 24‐week, multi‐centre, randomized, double‐b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jianping, Ling, Hongwei, Geng, Jianlin, Huang, Yanli, Xie, Ying, Zheng, Huiping, Niu, Huikun, Zhang, Tianhao, Yuan, Jing, Xiao, Xinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796963/ https://www.ncbi.nlm.nih.gov/pubmed/35791646 http://dx.doi.org/10.1111/dom.14810

Ejemplares similares

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
por: Moon, Jun Sung, et al.
Publicado: (2023)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
por: Han, Kyung Ah, et al.
Publicado: (2023)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Protective Effect of CXCR4 Antagonist DBPR807 against Ischemia-Reperfusion Injury in a Rat and Porcine Model of Myocardial Infarction: Potential Adjunctive Therapy for Percutaneous Coronary Intervention
por: Yeh, Kai-Chia, et al.
Publicado: (2022)

AB108. Vascularized bone marrow transplantation with renal transplantation
por: Wei, Di, et al.
Publicado: (2014)

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
por: Yang, Wenying, et al.
Publicado: (2022)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

R108
por: CERN PhotoLab
Publicado: (1976)

At R108
por: CERN PhotoLab
Publicado: (1977)

At R108
por: CERN PhotoLab
Publicado: (1977)

At R108
por: CERN PhotoLab
Publicado: (1977)

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)
por: Ellegaard, Pernille Kempel, et al.
Publicado: (2018)

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension
por: Jin, S.‐M., et al.
Publicado: (2015)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Yang, Hae Kyung, et al.
Publicado: (2019)

Darmstadt: Element 108
Publicado: (1984)

Darmstadt : Elément 108
Publicado: (1984)

Memorandum: Experiment S 108
por: CERN. Geneva, et al.
Publicado: (1971)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
por: Hirose, Takahisa, et al.
Publicado: (2015)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients
por: Scheen, André J
Publicado: (2020)

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study
por: Bourin, Michel S, et al.
Publicado: (2014)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma
por: Valtorta, Silvia, et al.
Publicado: (2021)

Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
por: Guarnaccia, Laura, et al.
Publicado: (2022)

Scheduling of experiment R108
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1974)

108th LHCC Meeting
Publicado: (2011)

Anything wrong with $108^{o}$?
por: Verdier, A
Publicado: (1997)

Assembling the detector for R108
por: CERN PhotoLab
Publicado: (1976)

Author Index for Volume 108
Publicado: (2013)

Keyword Index for Volume 108
Publicado: (2013)

Subject index for volume 108
Publicado: (1981)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
por: Wook Lee, Jong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n5hjlu8rm383crekj0ufu372r8